Antares Pharma (AIS) Rips on Anturol NDA Acceptance from FDA
Tweet
Share
E-mailGet Alerts AIS Hot Sheet
Join SI Premium – FREE
Antares Pharma Inc. (AMEX: AIS) shares are rocking pre-market today, following reports that the U.S. Food and Drug Administration has accepted its New Drug Application for Anturol Gel for review.
Antares Pharma stock is up 8.3 percent ahead of the bell today.
According to the release, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of December 8, 2011, ten months from the official NDA filing. The PDUFA date is the target date for the FDA to complete its review of the NDA.
Antares Pharma stock is up 8.3 percent ahead of the bell today.
According to the release, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of December 8, 2011, ten months from the official NDA filing. The PDUFA date is the target date for the FDA to complete its review of the NDA.
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
